Question · Q3 2025
Joshua Tassaro, on behalf of Cory Kasimov, asked about the decision to advance pomitamic into gastric cancer, inquiring whether it was based on compelling clinical data (and if so, whether it had been presented) or primarily on the understanding of the mechanism of action.
Answer
Uğur Şahin, Chief Executive Officer and Co-founder, confirmed that BioNTech has emerging data for pomitamic in gastric cancer. He noted that it's an indication where checkpoint blockade is approved, responses have been observed in combination with chemotherapy, and there's clear room for improvement over standard of care based on data from other GI indications, supported by a strong mechanistic rationale.